SEngine Precision Medicine

SEngine Precision Medicine, Inc.SEngine Precision Medicine, Inc. specializes in personalized cancer treatment solutions and was founded in 2015 in Seattle, US. The founder, Tom Neary, has experience in the biotech sector, establishing a firm committed to advancing cancer care.SEngine Precision Medicine specializes in personalized cancer treatment solutions through its flagship product, the PARIS® Test. This CLIA-certified platform evaluates patients’ tumor samples using a customized panel of up to 42 oncology drugs selected from a library of approximately 200 curated and validated treatments. Designed to provide actionable insights, the PARIS® Test serves oncologists by identifying potentially effective therapies for individual patients, including FDA-approved targeted therapies, chemotherapies, and investigational drugs under clinical trials. The primary end users of this service are oncologists, cancer patients, and healthcare institutions seeking advanced and tailored treatment options.SEngine Precision Medicine generates revenue through the provision of its PARIS® Test, which is offered directly to healthcare providers and oncologists. The transaction structure is primarily B2B, with the lab providing actionable reports to medical professionals following the analysis of patient samples. Revenue is derived from fees associated with each test conducted, reflecting the personalized nature of the service. The pricing structure is designed to accommodate healthcare providers, ensuring that they can access the test for their patients efficiently.In July 2022, SEngine Precision Medicine, Inc. There are ongoing efforts to explore new markets and geographic regions for expansion, although specific targets have not been disclosed.

1. Series A

   Jul 28, 2022

   Amount

   $10M

   Investors

   Locked

2. Series A

   Oct 2, 2019

   Amount

   $5.1M

   Investors

   Locked